CellVoyant—an artificial intelligence (AI) first biotechnology company spun out of the University of Bristol—has raised £7.6 million in seed funding to speed up the development of novel cell therapies. According to a Jan. 16, 2024 press release, the funding was led by Octopus Ventures and included Horizon Ventures, Verve Ventures, and Air Street Capital as participants of the funding round.
The biotech’s primary aim is to use its platform, which combines advanced AI with live cell imaging, to develop novel stem cell therapies in a cost-effective way while also improving reliability and speed of development.
